Quick Summary
- The Deal Value: Eli Lilly will acquire Orna Therapeutics for an upfront payment plus milestones totaling up to $2.4 billion.
- Strategic Focus: The acquisition centers on “in vivo” CAR-T technology, which allows the body to generate its own therapeutic cells, bypassing the costly and complex lab-based (ex vivo) manufacturing process.
- Core Technology: Lilly gains access to Orna’s oRNA® (circular RNA) platform and lipid nanoparticle (LNP) delivery system, which offers more durable protein expression than traditional mRNA.
- Lead Candidate: The primary asset is ORN-252, a CD19-targeting therapy ready for clinical trials, aimed at treating B cell-driven autoimmune diseases.
- Portfolio Diversification: This move follows a massive $8.5 billion pact with Innovent Biologics, highlighting Lilly’s strategy to use its “GLP-1 cash” to dominate immunology and oncology sectors.
Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics today announced a definitive agreement for Lilly to acquire Orna, a biotechnology leader at the forefront of circular RNA (oRNA®) technology. The acquisition, valued at up to $2.4 billion, underscores Lilly’s aggressive expansion into genetic medicine and its commitment to developing next-generation treatments for B-cell-driven autoimmune diseases.
A New Frontier: In Vivo CAR-T
The centerpiece of the acquisition is Orna’s proprietary platform, which combines engineered circular RNA with novel lipid nanoparticles (LNPs). Unlike traditional “ex vivo” CAR-T therapies, which require the complex, costly process of removing a patient’s cells, modifying them in a lab, and re-infusing them, Orna’s technology is designed to work in vivo. This allows the patient’s own body to act as the manufacturing site for therapeutic cells, potentially offering a simpler, more scalable, and more affordable alternative.
Read More: Lilly to Bolster Immunology Pipeline with $1.2 Billion Acquisition of Ventyx Biosciences
Lead Candidate: ORN-252
Lilly will gain access to Orna’s lead program, ORN-252, a clinical trial-ready, CD19-targeting in vivo CAR-T therapy. ORN-252 is specifically designed to treat B-cell-driven autoimmune diseases by resetting the immune system. Preclinical data suggest that Orna’s circular RNA provides more durable protein expression than traditional mRNA, which could lead to more effective and lasting treatments for chronic conditions.
Early autologous CAR-T studies have shown the promise of cell therapy for patients with autoimmune diseases, but the complexity and logistics of ex vivo approaches make it challenging to deliver these breakthroughs to a broader population,
Francisco Ramírez-Valle
Orna expects to initiate first-in-human studies for ORN-252 in early 2026, marking a pivotal transition from a platform-based biotech to a clinical-stage pioneer.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Financial Terms and Strategic Context
Under the terms of the agreement, Lilly will acquire all outstanding shares of Orna Therapeutics. The total consideration of up to $2.4 billion includes an upfront cash payment and subsequent payments contingent upon the achievement of specific clinical development milestones.
This deal is part of a broader “innovation spree” by Lilly, which recently surpassed a $1 trillion market cap. Just days prior to this announcement, Lilly revealed a major collaboration with Innovent Biologics, reinforcing its strategy to dominate the immunology and oncology sectors through both internal R&D and strategic M&A.
About Orna Therapeutics
Based in Watertown, Massachusetts, Orna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA®) therapeutics. By pairing oRNA with proprietary LNP delivery systems, Orna aims to treat diseases anywhere in the body by engineering cells in situ.
Last Modified:
